NS5A replication complex inhibitor daclatasvir in the basis of chronic hepatitis C interferon-free therapy
The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver cirrhosis, within different modes of treatment...
Saved in:
Main Authors: | M. V. Mayevskaya, M. S. Zharkova, V. T. Ivashkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2015-12-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/1037 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study
by: T. Berg, et al.
Published: (2019-01-01) -
Efficacy and safety of new protease inhibitor faldaprevir in treatment of hepatitis C
by: M. V. Mayevskaya, et al.
Published: (2013-12-01) -
Interferon-free therapy of chronic hepatitis C: replacement of medications or new treatment paradigm?
by: S. N. Batskikh
Published: (2014-10-01) -
A multiplex method for rapidly identifying viral protease inhibitors
by: Seo Jung Hong, et al.
Published: (2025-01-01) -
Modern modes of chronic hepatitis B treatment in daily clinical practice
by: M. V. Mayevskaya, et al.
Published: (2014-11-01)